Page 7 of 7
Are there any plans for further studies?
Some studies of niraparib and dostarlimab in participants with ovarian cancer have been
completed. Some GSK-sponsored studies are ongoing or planned.
Where can I find more information about this study?
Full title of this study: A phase 2 open-label, single-arm study to evaluate the efficacy and
safety of the combination of niraparib and dostarlimab (TSR-042) in patients with
platinum-resistant ovarian cancer (MOONSTONE).
Clinical studies have unique study numbers. The unique study number associated with this
study is shown below with an internet link to the scientific summary.
Organisation
Study Identifier
(Website)
United States National Institutes of Health (NIH)
NCT039554711
(www.clinicaltrials.gov)
The scientific summary includes more details about the requirements for study enrolment,
the study visit schedule, results from other endpoints, and more detailed information about
adverse events.
Your doctor can help you understand more about this study and the results. You
should not make changes to your care based on the results of this or any single study.
We would like to thank the participants who contributed to this study. The results of
this study will help answer scientific questions about treating participants with ovarian
cancer.
The content for this document was finalised by GSK on 12 July 2022. The information in this
summary does not include additional information available after this date.
1https://clinicaltrials.gov/ct2/show/NCT03955471